Related Experiment Video
Updated: May 7, 2026

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
Published on: December 11, 2016
Revisiting methotrexate and phototrexate Zinc15 library-based derivatives using deep learning in-silico drug design
Farhan Siddique1,2, Ahmar Anwaar3, Maryam Bashir2,4
1School of Pharmaceutical Science and Technology, Tianjin University, Tianjin, China.
Abstract:
Introduction: Cancer is the second most prevalent cause of mortality in the world, despite the availability of several medications for cancer treatment. Therefore, the cancer research community emphasized on computational techniques to speed up the discovery of novel anticancer drugs. Methods: In the current study, QSAR-based virtual screening was performed on the Zinc15 compound library (271 derivatives of methotrexate (MTX) and phototrexate (PTX)) to predict their inhibitory activity against dihydrofolate reductase (DHFR), a potential anticancer drug target. The deep learning-based ADMET parameters were employed to generate a 2D QSAR model using the multiple linear regression (MPL) methods with Leave-one-out cross-validated (LOO-CV) Q2 and correlation coefficient R2 values as high as 0.77 and 0.81, respectively. Results: From the QSAR model and virtual screening analysis, the top hits (09, 27, 41, 68, 74, 85, 99, 180) exhibited pIC50 ranging from 5.85 to 7.20 with a minimum binding score of -11.6 to -11.0 kcal/mol and were subjected to further investigation. The ADMET attributes using the message-passing neural network (MPNN) model demonstrated the potential of selected hits as an oral medication based on lipophilic profile Log P (0.19-2.69) and bioavailability (76.30% to 78.46%). The clinical toxicity score was 31.24% to 35.30%, with the least toxicity score (8.30%) observed with compound 180. The DFT calculations were carried out to determine the stability, physicochemical parameters and chemical reactivity of selected compounds. The docking results were further validated by 100 ns molecular dynamic simulation analysis. Conclusion: The promising lead compounds found endorsed compared to standard reference drugs MTX and PTX that are best for anticancer activity and can lead to novel therapies after experimental validations. Furthermore, it is suggested to unveil the inhibitory potential of identified hits via in-vitro and in-vivo approaches.
Insights
Computational methods identified novel anticancer drug candidates by screening methotrexate derivatives against the dihydrofolate reductase target. Promising compounds show good oral bioavailability and low toxicity, warranting further experimental validation for cancer therapy.
Area of Science:
- Computational chemistry and drug discovery
- Medicinal chemistry and pharmacology
Background:
- Cancer remains a leading cause of mortality globally, necessitating the development of new therapeutic agents.
- Computational techniques offer a promising avenue for accelerating the discovery of novel anticancer drugs.
Purpose of the Study:
- To perform QSAR-based virtual screening of methotrexate and phototrexate derivatives to identify novel inhibitors of dihydrofolate reductase (DHFR).
- To predict the anticancer potential, ADMET properties, and toxicity of identified compounds using computational models.
Main Methods:
- Quantitative Structure-Activity Relationship (QSAR) modeling using deep learning-based ADMET parameters and multiple linear regression (MPL).
- Virtual screening of 271 methotrexate (MTX) and phototrexate (PTX) derivatives against the DHFR target.
- Assessment of ADMET properties via message-passing neural network (MPNN) and density functional theory (DFT) calculations; molecular dynamics simulations for validation.
Main Results:
- QSAR model achieved high predictive accuracy (LOO-CV Q2=0.77, R2=0.81).
- Virtual screening identified eight top-hit compounds (09, 27, 41, 68, 74, 85, 99, 180) with significant predicted inhibitory activity (pIC50 5.85-7.20).
- Selected compounds exhibit favorable oral drug potential (Log P 0.19-2.69, bioavailability 76.30%-78.46%) and low clinical toxicity, with compound 180 showing the least toxicity (8.30%).
Conclusions:
- The identified lead compounds demonstrate superior or comparable anticancer potential to standard drugs MTX and PTX.
- These compounds represent promising candidates for novel anticancer therapies, pending experimental validation.
- Further in vitro and in vivo studies are recommended to confirm the inhibitory potential and efficacy of the identified hits.
More Related Videos
07:40A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions
Published on: May 27, 2021
13:17In Vitro and In Vivo Evaluation of Photocontrolled Biologically Active Compounds - Potential Drug Candidates for Cancer Photopharmacology
Published on: September 29, 2023
Related Concept Videos
Therapeutic Drug Monitoring: Affecting Factors
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Pharmacogenomics: Identification of New Drug Targets